Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyMagnesium salicylate
Identification
- Name
- Magnesium salicylate
- Accession Number
- DB01397
- Type
- Small Molecule
- Groups
- Experimental
- Description
Magnesium salicylate is a non-steroidal anti-inflammatory drug (NSAID) used to treat mild to moderate pain. It is available in several over-the-counter (OTC) formulations. Though the recommended doseage is 1160 mg every six hours, per package directions of the Doan's OTC brand (580 mg magnesium salicylate tetrahydrate, equivalent to 934.4 mg anhydrous magnesium salicylate), effective pain relief is often found with a half dosage, with reduced anti-inflammatory results.
- Structure
Structure for Magnesium salicylate (DB01397)
- Synonyms
- Magnesium salicylate
- Magnesium salicylate anhydrous
- Product Ingredients
Ingredient UNII CAS InChI Key Magnesium salicylate tetrahydrate 41728CY7UX 18917-95-8 NBQBEWAYWAMLJJ-UHFFFAOYSA-L - Active Moieties
Name Kind UNII CAS InChI Key Salicylic acid unknown O414PZ4LPZ 69-72-7 YGSDEFSMJLZEOE-UHFFFAOYSA-N - Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Unlock Additional DataArthriten Tablets Tablet Oral Alva Amco Pharmacal Companies, Inc. 2003-05-15 2006-07-27 Canada 
Back-ese M Tab 325mg Tablet Oral G.T. Fulford Pharmaceuticals 1985-12-31 1998-06-25 Canada Back-ese M Tablets 325 mg Tablet Oral Dannorth Laboratories Inc. 1980-12-31 2000-07-19 Canada Backache Aid Tablet, film coated 580 mg/1 Oral L&R Distributors, Inc. 1998-11-07 2021-08-03 US 
Backache Relief Tablet, film coated 580 mg/1 Oral Rite Aid Corporation 1998-11-07 Not applicable US Backache Relief Tablet, film coated 580 mg/1 Oral CVS PHARMACY 1998-11-07 2021-12-21 US Backache Relief Extra Strength Tablet, film coated 580 mg/1 Oral L.N.K. International, Inc. 1998-11-07 Not applicable US Backache Relief Extra Strength Tablet 580 mg/1 Oral Walgreen 1998-11-07 2018-04-10 US Doan's Backache Pills 325mg Tablet Oral Novartis 1988-12-31 1998-07-08 Canada Doans Extra Strength Tablet 580 mg/1 Oral Dr. Reddy's Laboratories Inc. 2016-05-24 Not applicable US Additional Data Available- Application NumberApplication Number
A unique ID assigned by the FDA when a product is submitted for approval by the labeller.
Learn more - Product CodeProduct Code
A governmentally-recognized ID which uniquely identifies the product within its regulatory market.
Learn more
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Arthriten Joint Pain Relief Magnesium salicylate tetrahydrate (310 mg/1) + Acetaminophen (250 mg/1) + Caffeine (32.5 mg/1) Tablet, film coated Oral Alva-Amco Pharmacal Companies, Inc. 2002-10-28 2010-05-17 US Back Relief Magnesium salicylate tetrahydrate (200 mg/1) + Acetaminophen (200 mg/1) Tablet Oral Honeywell Safety Products USA, Inc 2013-05-14 2017-12-20 US Back Relief Magnesium salicylate tetrahydrate (200 mg/1) + Acetaminophen (200 mg/1) Tablet Oral Honeywell Safety Products USA, Inc 2017-12-20 Not applicable US Diurex Water Pills Magnesium salicylate tetrahydrate (162.5 mg/1) + Caffeine (50 mg/1) Tablet, coated Oral Alva-Amco Pharmacal Companies, Inc. 2005-05-15 Not applicable US MEDIQUE Back Pain Off Magnesium salicylate tetrahydrate (290 mg/1) + Acetaminophen (250 mg/1) + Caffeine (50 mg/1) Tablet, film coated Oral Unifirst First Aid Corporation 2008-12-30 Not applicable US Otis Clapp Back Quell Magnesium salicylate tetrahydrate (200 mg/1) + Acetaminophen (200 mg/1) Tablet, film coated Oral Unifirst First Aid Corporation 2008-12-30 Not applicable US Pain Aid BRF Magnesium salicylate tetrahydrate (250 mg/1) + Acetaminophen (250 mg/1) Tablet Oral Zee Medical Inc 2012-08-19 Not applicable US Pamprin Cramp Menstrual Pain Relief Magnesium salicylate tetrahydrate (250 mg/1) + Acetaminophen (250 mg/1) + Pamabrom (25 mg/1) Tablet Oral Chattem, Inc. 1983-01-01 Not applicable US Trilisate Tab Magnesium salicylate (362 mg) + Choline salicylate (293 mg) Tablet Oral Purdue Pharma 1979-12-31 2002-07-30 Canada Vica-cet Magnesium salicylate tetrahydrate (250 mg/1) + Acetaminophen (250 mg/1) Tablet Oral Provision Medical 2015-04-03 Not applicable US - International/Other Brands
- Analate / Lorisal / Magan / Mobidin / Triact
- Categories
- Acids, Carbocyclic
- Agents causing hyperkalemia
- Agents that produce hypertension
- Analgesics
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Anti-Inflammatory Agents, Non-Steroidal (Non-Selective)
- Antirheumatic Agents
- Benzene Derivatives
- Benzoates
- Central Nervous System Agents
- Cyclooxygenase Inhibitors
- Enzyme Inhibitors
- Hydroxy Acids
- Hydroxybenzoates
- Magnesium Compounds
- Magnesium Salts
- Metal cations
- Metal divalent cations
- Nephrotoxic agents
- Non COX-2 selective NSAIDS
- Peripheral Nervous System Agents
- Phenols
- Sensory System Agents
- UNII
- JQ69D454N1
- CAS number
- 18917-89-0
- Weight
- Average: 298.531
Monoisotopic: 298.03277995 - Chemical Formula
- C14H10MgO6
- InChI Key
- MQHWFIOJQSCFNM-UHFFFAOYSA-L
- InChI
- InChI=1S/2C7H6O3.Mg/c2*8-6-4-2-1-3-5(6)7(9)10;/h2*1-4,8H,(H,9,10);/q;;+2/p-2
- IUPAC Name
- magnesium(2+) ion bis(2-hydroxybenzoate)
- SMILES
- [Mg++].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Pharmacology
- Indication
Magnesium salicylate is a common analgesic and non-steroidal anti-inflammatory drug (NSAID) used to treat mild to moderate muscular pain
- Pharmacodynamics
- Not Available
- Mechanism of action
Most NSAIDs act as nonselective inhibitors of the enzyme cyclooxygenase (COX), inhibiting both the cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) isoenzymes. COX catalyzes the formation of prostaglandins and thromboxane from arachidonic acid (itself derived from the cellular phospholipid bilayer by phospholipase A2). Prostaglandins act (among other things) as messenger molecules in the process of inflammation.
Target Actions Organism AProstaglandin G/H synthase 2 inhibitorHumans AProstaglandin G/H synthase 1 inhibitorHumans - Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
Pathway Category Magnesium Salicylate Action Pathway Drug action - Pharmacogenomic Effects/ADRs
- Not Available
Unlock Additional Data
Additional Data Available
Adverse Effects
Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.
Learn more Additional Data Available
Contraindications
Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.
Learn more Additional Data Available
Blackbox Warnings
Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.
Learn moreInteractions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Unlock Additional Data(R)-warfarin The risk or severity of bleeding and hemorrhage can be increased when Magnesium salicylate is combined with (R)-warfarin. (S)-Warfarin The risk or severity of bleeding and hemorrhage can be increased when Magnesium salicylate is combined with (S)-Warfarin. 1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid The risk or severity of hypertension can be increased when Magnesium salicylate is combined with 1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid. 1-benzylimidazole The risk or severity of hypertension can be increased when Magnesium salicylate is combined with 1-benzylimidazole. 1alpha-Hydroxyvitamin D5 The serum concentration of Magnesium salicylate can be increased when it is combined with 1alpha-Hydroxyvitamin D5. 1alpha,24S-Dihydroxyvitamin D2 The serum concentration of Magnesium salicylate can be increased when it is combined with 1alpha,24S-Dihydroxyvitamin D2. 2,5-Dimethoxy-4-ethylamphetamine The risk or severity of hypertension can be increased when Magnesium salicylate is combined with 2,5-Dimethoxy-4-ethylamphetamine. 2,5-Dimethoxy-4-ethylthioamphetamine The risk or severity of hypertension can be increased when Magnesium salicylate is combined with 2,5-Dimethoxy-4-ethylthioamphetamine. 3-Aza-2,3-Dihydrogeranyl Diphosphate Magnesium salicylate can cause a decrease in the absorption of 3-Aza-2,3-Dihydrogeranyl Diphosphate resulting in a reduced serum concentration and potentially a decrease in efficacy. 4-Bromo-2,5-dimethoxyamphetamine The risk or severity of hypertension can be increased when Magnesium salicylate is combined with 4-Bromo-2,5-dimethoxyamphetamine. Additional Data Available- Extended DescriptionExtended Description
Extended description of the mechanism of action and particular properties of each drug interaction.
Learn more - Severity
- Evidence Level
- ActionAction
An effect category for each drug interaction. Know how this interaction affects the subject drug.
Learn more
- Food Interactions
- Not Available
References
- Synthesis Reference
Satishchandra P. Patel, Vinayak T. Bhalani, "Solid choline magnesium salicylate composition and method of preparing same." U.S. Patent US5043168, issued May, 1954.
US5043168- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0015469
- KEGG Compound
- C07995
- PubChem Compound
- 54684589
- PubChem Substance
- 46508713
- ChemSpider
- 58278
- ChEBI
- 6640
- ChEMBL
- CHEMBL2106755
- PharmGKB
- PA450300
- Wikipedia
- Magnesium_salicylate
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Caraco Pharmaceutical Labs
- CVS Pharmacy
- Ivax Pharmaceuticals
- Key Co.
- Novartis AG
- Palmetto Pharmaceuticals Inc.
- Qualitest
- US Pharmaceutical Corp.
- Dosage forms
Form Route Strength Tablet, film coated Oral Tablet Oral Tablet, film coated Oral 580 mg/1 Tablet Oral 580 mg/1 Tablet, coated Oral Capsule Oral 580 mg/1 Tablet, coated Oral 467 mg/1 Tablet Oral - Prices
Unit description Cost Unit Tricosal 1000 mg tablet 1.23USD tablet Choline mag trisal 1 gm tablet 1.15USD tablet Choline mag trisal 750 mg tablet 0.81USD tablet Novasal 600 mg tablet 0.75USD tablet Choline mag trisal 500 mg tablet 0.64USD tablet Doan's ex strength 580 mg tablet 0.22USD tablet CVS Pharmacy backache rlf 580 mg caplet 0.18USD caplet Doan's regular 325 mg tablet 0.18USD tablet Keygesic-10 650 mg tablet 0.05USD tablet DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0686 mg/mL ALOGPS logP 2.86 ALOGPS logP 1.98 ChemAxon logS -3.6 ALOGPS pKa (Strongest Acidic) 2.79 ChemAxon pKa (Strongest Basic) -6.3 ChemAxon Physiological Charge -1 ChemAxon Hydrogen Acceptor Count 3 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 60.36 Å2 ChemAxon Rotatable Bond Count 2 ChemAxon Refractivity 46.13 m3·mol-1 ChemAxon Polarizability 12.38 Å3 ChemAxon Number of Rings 2 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.5741 Blood Brain Barrier + 0.829 Caco-2 permeable + 0.5941 P-glycoprotein substrate Non-substrate 0.6758 P-glycoprotein inhibitor I Non-inhibitor 0.9704 P-glycoprotein inhibitor II Non-inhibitor 0.9768 Renal organic cation transporter Non-inhibitor 0.8975 CYP450 2C9 substrate Non-substrate 0.7872 CYP450 2D6 substrate Non-substrate 0.9101 CYP450 3A4 substrate Non-substrate 0.7282 CYP450 1A2 substrate Non-inhibitor 0.8837 CYP450 2C9 inhibitor Non-inhibitor 0.5705 CYP450 2D6 inhibitor Non-inhibitor 0.9113 CYP450 2C19 inhibitor Non-inhibitor 0.8537 CYP450 3A4 inhibitor Non-inhibitor 0.9421 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9021 Ames test Non AMES toxic 0.9695 Carcinogenicity Non-carcinogens 0.8587 Biodegradation Ready biodegradable 0.8277 Rat acute toxicity 2.3552 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.952 hERG inhibition (predictor II) Non-inhibitor 0.9555
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as salicylic acids. These are ortho-hydroxylated benzoic acids.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Benzoic acids and derivatives
- Direct Parent
- Salicylic acids
- Alternative Parents
- Benzoic acids / Benzoyl derivatives / 1-hydroxy-4-unsubstituted benzenoids / 1-hydroxy-2-unsubstituted benzenoids / Vinylogous acids / Carboxylic acid salts / Monocarboxylic acids and derivatives / Carboxylic acids / Organooxygen compounds / Organic salts show 2 more
- Substituents
- Salicylic acid / Benzoic acid / Benzoyl / 1-hydroxy-4-unsubstituted benzenoid / 1-hydroxy-2-unsubstituted benzenoid / Phenol / Vinylogous acid / Carboxylic acid salt / Monocarboxylic acid or derivatives / Carboxylic acid show 7 more
- Molecular Framework
- Not Available
- External Descriptors
- benzenes, carbonyl compound (CHEBI:6640)
Targets
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Prostaglandin-endoperoxide synthase activity
- Specific Function
- Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
- Gene Name
- PTGS2
- Uniprot ID
- P35354
- Uniprot Name
- Prostaglandin G/H synthase 2
- Molecular Weight
- 68995.625 Da
References
- Graham GG, Scott KF: Mechanisms of action of paracetamol and related analgesics. Inflammopharmacology. 2003;11(4):401-13. [PubMed:15035793]
- Fiebich BL, Chrubasik S: Effects of an ethanolic salix extract on the release of selected inflammatory mediators in vitro. Phytomedicine. 2004 Feb;11(2-3):135-8. [PubMed:15070163]
- Chae HJ, Chae SW, Reed JC, Kim HR: Salicylate regulates COX-2 expression through ERK and subsequent NF-kappaB activation in osteoblasts. Immunopharmacol Immunotoxicol. 2004 Feb;26(1):75-91. [PubMed:15106733]
- Wu KK: Aspirin and other cyclooxygenase inhibitors: new therapeutic insights. Semin Vasc Med. 2003 May;3(2):107-12. [PubMed:15199473]
- Elvira C, Gallardo A, Lacroix N, Schacht E, San Roman J: Incorporation of salicylic acid derivatives to hydrophilic copolymer systems with biomedical applications. J Mater Sci Mater Med. 2001 Jun;12(6):535-42. [PubMed:15348270]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Prostaglandin-endoperoxide synthase activity
- Specific Function
- Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
- Gene Name
- PTGS1
- Uniprot ID
- P23219
- Uniprot Name
- Prostaglandin G/H synthase 1
- Molecular Weight
- 68685.82 Da
References
- Moon C, Ahn M, Jee Y, Heo S, Kim S, Kim H, Sim KB, Koh CS, Shin YG, Shin T: Sodium salicylate-induced amelioration of experimental autoimmune encephalomyelitis in Lewis rats is associated with the suppression of inducible nitric oxide synthase and cyclooxygenases. Neurosci Lett. 2004 Feb 12;356(2):123-6. [PubMed:14746879]
- Graham GG, Scott KF: Mechanisms of action of paracetamol and related analgesics. Inflammopharmacology. 2003;11(4):401-13. [PubMed:15035793]
- Sun R, Carlson NG, Hemmert AC, Kishore BK: P2Y2 receptor-mediated release of prostaglandin E2 by IMCD is altered in hydrated and dehydrated rats: relevance to AVP-independent regulation of IMCD function. Am J Physiol Renal Physiol. 2005 Sep;289(3):F585-92. Epub 2005 Apr 19. [PubMed:15840771]
- Celik G, Pasaoglu G, Bavbek S, Abadoglu O, Dursun B, Mungan D, Misirligil Z: Tolerability of selective cyclooxygenase inhibitor, celecoxib, in patients with analgesic intolerance. J Asthma. 2005 Mar;42(2):127-31. [PubMed:15871445]
- Liu X, Lee TL, Wong PT: Cyclooxygenase-1 inhibition shortens the duration of diazepam-induced loss of righting reflex in mice. Anesth Analg. 2006 Jan;102(1):135-40. [PubMed:16368818]
Carriers
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- General Function
- Toxic substance binding
- Specific Function
- Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
- Gene Name
- ALB
- Uniprot ID
- P02768
- Uniprot Name
- Serum albumin
- Molecular Weight
- 69365.94 Da
References
- Zhang Q, Huang Y, Zhao R, Liu G, Chen Y: Determining binding sites of drugs on human serum albumin using FIA-QCM. Biosens Bioelectron. 2008 Sep 15;24(1):48-54. doi: 10.1016/j.bios.2008.03.009. Epub 2008 Mar 21. [PubMed:18436441]
Drug created on July 08, 2007 11:04 / Updated on December 02, 2019 05:49